Myriad Genetics, Inc. (MYGN) NASDAQ
4.80
+0.05(+1.05%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
4.80
+0.05(+1.05%)
Currency In USD
| Previous Close | 4.75 |
| Open | 4.7 |
| Day High | 5.06 |
| Day Low | 4.7 |
| 52-Week High | 8.59 |
| 52-Week Low | 3.76 |
| Volume | 1.94M |
| Average Volume | 1.73M |
| Market Cap | 448.84M |
| PE | -1.22 |
| EPS | -3.95 |
| Moving Average 50 Days | 4.77 |
| Moving Average 200 Days | 6.04 |
| Change | 0.05 |
Myriad Commercially Launches Precise MRD with Select Community Oncologists
GlobeNewswire Inc.
Mar 02, 2026 9:05 PM GMT
Launch Represents Significant Step to Broader CommercializationSALT LAKE CITY, March 02, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces the launch of t
Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk tests
GlobeNewswire Inc.
Feb 24, 2026 2:00 PM GMT
SALT LAKE CITY, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will present new data at the 2026 ASCO-GU conference supporting its Precise MRDTM (Molecular R
FirstGene Study Demonstrates High Analytical Sensitivity and Specificity for Each Component of the Test
GlobeNewswire Inc.
Feb 19, 2026 2:15 PM GMT
Analytical validation of FirstGene Multiple Prenatal Screen published in Clinical ChemistrySALT LAKE CITY, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, anno